Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Mandy Jackson

Mandy Jackson is the US West Coast Editor for Scrip Intelligence. Mandy reports on daily biopharma news and regularly interviews everyone from big pharma CEOs to biotech startup founders about the business strategy behind their finance, dealmaking and drug development news. She also has an interest in drug pricing and novel reimbursement strategies, new treatments in areas of true unmet need, and business development trends. Mandy has been a business news reporter for more than 15 years, covering biotech and pharma companies, biotech law and commercial real estate. She is based in San Diego, California – the venue for many medical and biopharma industry meetings.
Advertisement
Set Alert for Articles By Mandy Jackson

Latest From Mandy Jackson

Aerie's M&A Potential Rises As Roclatan Passes Second Phase III Glaucoma Test

Positive Phase III data for Aerie's second glaucoma drug candidate Roclatan – which will support a US FDA submission in the first half of 2018 – have boosted the California company's M&A allure.

Research & Development Clinical Trials

Neurocrine Blames Sub-Par Dosing For Ingrezza Study Failure

Neurocrine's stock fell 9% on May 24 after the company said a closely-watched Phase II study for Ingrezza in pediatric Tourette's syndrome failed, but blamed a sub-therapeutic dose for the disappointing results. Most analysts gave the prospects for a higher dose study the benefit of the doubt.

Clinical Trials Neurology

Bioverativ Fills Gap In Pipeline With $400m True North Buy

Bioverativ revealed its first transaction since spinning out from Biogen with the acquisition of True North for $400m plus up to $425m in milestone payments. The deal gives Bioverativ a clinical asset, helping to fill the gap between preclinical programs and commercial products in its R&D pipeline.

Deals Business Strategies

Shire Discontinues Development Of Once-Weekly SHP656 For Hemophilia A

Shire's cash-strapped partner Xenetic, whose technology enabled the long-acting Factor VIII, said on May 22 that SHP656 could not achieve once-weekly dosing in a Phase I/II clinical trial. The market for such a product may be limited anyway given current competition and payer preferences.

Research & Development Commercial

Finance Watch: Two More US Biopharma IPOs And Two New European VC Funds

Two biopharma IPOs in the US continue streak of (mostly) positive returns; two new European VC funds launch as Irish antibiotic developer raises $65m; and Halozyme, Ziopharm price offerings.

Business Strategies Commercial

It's Not All About IO: Seven Drugs To Watch At ASCO

Biomedtracker's review of ASCO abstracts revealed several drugs to watch outside of the immuno-oncology space at the annual cancer conference in Chicago, including market-expanding data for Roche's Perjeta and J&J's Zytiga, and Phase III data for AstraZeneca's PARP inhibitor Lynparza in breast cancer.

Clinical Trials Commercial
See All
Advertisement
UsernamePublicRestriction

Register